Adenovectors Adenoviruses have been widely used as vectors for the transfer of genes. In spite of one highly publicized death in a gene therapy trial, excellent safety precedents exist. Adenovirus-based vaccines have been used in humans for 30 years, vaccinating all US military recruits, without any serious side effects. First generation adenovectors presently in the clinic and in research laboratories are providing the knowledge base for the development of improved systems for gene transfer and drug delivery. First generation adenovectors have been used to dose thousands of patients in clinical trials and two vectors have already been approved in China for the treatment of solid tumors. The major advantages of adenovectors are: • large amounts of vectors can be produced • ability to transduce both fast and slow growing cells • ability to transduce a wide variety of cell types • ability to accommodate large fragments of foreign genetic material However, first generation vectors have limitations as well. These include: • lack of sustained expression • lack of efficiency in some clinically relevant cancer cells • possible toxicity at high doses due to absence of cell and tissue specificity • inability to multiple dose because of the human body’s defense reactions against   the vector VectorLogics has developed three major technologies to achieve fundamental improvements and address major hurdles in adenovector-based biological drug delivery. These improvements are in: • targeting efficiency • targeting selectivity • genetic specificity   The adenovectors developed by VLI constitute a major paradigm shift in the development of next generation vectors, compared to vectors used in the clinic today. VLI has developed innovative technologies that modify the adenovector outer coat proteins to significantly increase their effectiveness. These technologies can be applied to different treatment modalities or can be combined in a single vector for maximum efficacy and safety.